Aortofemoral bypass in young patients with premature atherosclerosis: is superficial femoral vein superior to Dacron?
| Autor: | Mark R. Jackson, M.Burress Welborn, J. Gregory Modrall, Victor J. D’Addio, Eva Scoggins, Ahsan T. Ali, R. James Valentine, Christopher L. Bell, G. Patrick Clagett |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Arteriosclerosis medicine.medical_treatment Aortic Diseases Femoral vein Aortoiliac occlusive disease Biocompatible Materials Fasciotomy Coronary artery disease Blood Vessel Prosthesis Implantation fluids and secretions Blood vessel prosthesis medicine Humans Derivation Polyethylene Terephthalates business.industry Vascular disease Age Factors Graft Occlusion Vascular Femoral Vein Middle Aged medicine.disease bacterial infections and mycoses Blood Vessel Prosthesis Surgery respiratory tract diseases Femoral Artery Treatment Outcome Female Superficial vein business Cardiology and Cardiovascular Medicine |
| Zdroj: | Journal of Vascular Surgery. 40(1):17-23 |
| ISSN: | 0741-5214 |
| DOI: | 10.1016/j.jvs.2004.04.002 |
| Popis: | PurposePrevious studies have documented poor patency rates in “young” patients (age 55 years or younger) with premature atherosclerosis undergoing aortofemoral bypass (AFB) to treat aortoiliac occlusive disease. Given the high reported graft patency rates with superficial femoral vein (SFV) grafts performed because of aortic graft infection, we evaluated the role of SFV grafts for AFB as primary therapy for premature atherosclerosis in a case-control study.MethodsOver 10 years 31 patients aged 55 year or younger underwent AFB with use of SFV (V-AFB). Case controls consisted of all patients 55 years of age or younger who underwent AFB with use of Dacron (D-AFB) during the same period (n = 80). In all cases this was the initial therapy (no repeat operations). The two groups were well matched for age, sex, weight, preoperative ankle-brachial index, and the comorbid conditions of smoking, coronary artery disease, chronic obstructive pulmonary disease, hyperlipidemia, hypertension, and renal insufficiency. There were more patients with diabetes in the V-AFB group (34% vs 16%; P = .05). Patients in the V-AFB group had more advanced disease, and the surgical indication was more frequently critical ischemia compared with the D-AFB group (90% vs 46%; P < .001).ResultsThere was only one perioperative death in each group. There were no differences in cardiac, pulmonary, or gastrointestinal complications. However, fasciotomy occurred more frequently with V-AFB (44% vs 1%; P < .001). Surgery time was longer with V-AFB (7.3 vs 4.5 hours; P < .001). Despite these short-term drawbacks, V-AFB proved superior at long-term follow-up. The 5-year primary patency rate was significantly higher with V-AFB than with D-AFB (100% vs 56%; P = .013). There was also a trend for higher limb salvage at 5 years (90% vs 62%). Four graft infections occurred with D-AFB, and none with V-AFB (P = .32).ConclusionsAFB performed with SFV grafts is a far more durable operation than standard D-AFB in young patients with aortoiliac occlusive disease. However, V-AFB is far more likely to require lower extremity fasciotomy, and takes almost twice as long to perform. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|